Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Abivax SA American Depositary Shares (ABVX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
11/05/2025: ABVX (3-star) is a STRONG-BUY. BUY since 105 days. Simulated Profits (1177.05%). Updated daily EoD!
Upturn Star Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Number of Analysts
7 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $117.25
1 Year Target Price $117.25
| 4 | Strong Buy |
| 2 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 1152.85% | Avg. Invested days 71 | Today’s Advisory Strong Buy |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 11/05/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 7.92B USD | Price to earnings Ratio - | 1Y Target Price 117.25 |
Price to earnings Ratio - | 1Y Target Price 117.25 | ||
Volume (30-day avg) 7 | Beta -0.11 | 52 Weeks Range 4.77 - 108.00 | Updated Date 11/6/2025 |
52 Weeks Range 4.77 - 108.00 | Updated Date 11/6/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.55 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -4440.88% |
Management Effectiveness
Return on Assets (TTM) -57.74% | Return on Equity (TTM) -499.78% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 6419886799 | Price to Sales(TTM) 1314.21 |
Enterprise Value 6419886799 | Price to Sales(TTM) 1314.21 | ||
Enterprise Value to Revenue 157.63 | Enterprise Value to EBITDA -12.66 | Shares Outstanding 77828918 | Shares Floating 35270718 |
Shares Outstanding 77828918 | Shares Floating 35270718 | ||
Percent Insiders - | Percent Institutions 46.24 |
Upturn AI SWOT
Abivax SA American Depositary Shares
Company Overview
History and Background
Abivax SA is a clinical-stage biotechnology company founded in 2013 in France. It focuses on developing novel therapies to treat inflammatory diseases, viral infections, and cancer. The company has evolved through various clinical trials and strategic partnerships.
Core Business Areas
- Immunotherapies: Developing therapies to modulate the immune system for treating inflammatory diseases and viral infections.
- Clinical Trials: Conducting clinical trials for its lead drug candidate, obefazimod, and other pipeline products.
Leadership and Structure
Abivax is led by a management team with experience in the biotechnology industry. Its organizational structure includes departments for research and development, clinical operations, and corporate affairs.
Top Products and Market Share
Key Offerings
- Obefazimod: Obefazimod is Abivax's lead drug candidate, a first-in-class oral drug candidate for the treatment of ulcerative colitis and Crohn's disease. It is currently undergoing Phase 3 clinical trials. No current market share as it is still under development. Competitors include marketed therapies from Johnson & Johnson (JNJ) and AbbVie (ABBV).
Market Dynamics
Industry Overview
The biotechnology industry is characterized by high research and development costs, lengthy regulatory approval processes, and intense competition. Growth is driven by innovation and unmet medical needs.
Positioning
Abivax is positioned as an innovative player in the immunotherapy space, focusing on novel mechanisms of action for treating inflammatory diseases.
Total Addressable Market (TAM)
The global inflammatory bowel disease (IBD) market is projected to reach billions of dollars. Abivax is positioned to capture a portion of this market with its obefazimod candidate, pending successful clinical trials and regulatory approvals.
Upturn SWOT Analysis
Strengths
- Novel drug candidate (obefazimod)
- Experienced management team
- Strong intellectual property portfolio
Weaknesses
- Reliance on successful clinical trial outcomes
- Limited commercialization experience
- High cash burn rate
Opportunities
- Positive clinical trial results for obefazimod
- Partnerships with larger pharmaceutical companies
- Expansion into new therapeutic areas
Threats
- Failure of clinical trials
- Competition from established pharmaceutical companies
- Regulatory hurdles
- Financing risks
Competitors and Market Share
Key Competitors
- JNJ
- ABBV
- BMY
Competitive Landscape
Abivax faces competition from established pharmaceutical companies with approved therapies for inflammatory bowel disease. Its competitive advantage lies in its novel mechanism of action and potential for improved efficacy and safety.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is characterized by the progress of its drug development pipeline and increases in market capitalization.
Future Projections: Future growth depends on the successful completion of clinical trials and the potential commercialization of obefazimod.
Recent Initiatives: Recent initiatives include the initiation and progression of Phase 3 clinical trials for obefazimod in ulcerative colitis.
Summary
Abivax is a clinical-stage biotech company with a promising drug candidate, obefazimod, targeting ulcerative colitis and Crohn's disease. The company's success hinges on positive clinical trial outcomes and potential partnerships. Its reliance on R&D spending and absence of revenue currently makes it high-risk. They need to look out for clinical trial results and competition from big pharma.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company Filings
- Analyst Reports
- Industry News
Disclaimers:
The information provided is for informational purposes only and should not be considered investment advice. Market share data are estimates and may vary.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Abivax SA American Depositary Shares
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2023-10-20 | CEO & Director Mr. Marc M. P. de Garidel M.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 69 | Website https://www.abivax.com |
Full time employees 69 | Website https://www.abivax.com | ||
ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod that is in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis, as well as in Phase 2b clinical trial to treat patients with Crohn's disease. The company was incorporated in 2013 and is headquartered in Paris, France.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.